IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

Elisa A RozemanJudith M VersluisKarolina SikorskaEsmée P HoefsmitPetros DimitriadisDisha RaoRuben LacroixLindsay G Grijpink-OngeringMarta Lopez-YurdaBirthe C HeeresBart A van de WielClaudie FlohilAysegul SariStijn W T P J HeijminkDaan van den BroekAnnegien BroeksJan Willem B de GrootMarieke A VolleberghSofie WilgenhofJohannes V van ThienenJohn B A G HaanenChristian U Blank

Published in: Journal for immunotherapy of cancer (2023)

NCT02625337.

Keyphrases

advanced non small cell lung cancer
signaling pathway
open label
oxidative stress
high intensity
pi k akt
epidermal growth factor receptor
double blind
randomized controlled trial
cell proliferation
tyrosine kinase
basal cell carcinoma